XOMA Corp

XOMA Royalty Corporation is a biotechnology royalty aggregator that acquires potential future economics — including milestone payments and royalties — associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company provides non-dilutive, non-recourse funding to biotech sellers in exchange for rights to future payment streams. XOMA's growing portfolio includes over 120 assets spanning commercial products and clinical-stage candidates across multiple therapeutic areas. Its commercial royalty-generating assets include VABYSMO (wet AMD, DME, RVO), OJEMDA (pediatric low-grade glioma), MIPLYFFA (Niemann-Pick Disease Type C), IXINITY (Hemophilia B), XACIATO (bacterial vaginosis), DSUVIA (acute pain), and DARE to PLAY Sildenafil Cream (FSAD). The company differentiates itself by focusing on early- to mid-stage clinical assets at lower capital per transaction compared to larger royalty companies, and has expanded its model to include acquisitions of small biotech companies to access partnered royalty and milestone streams along with non-dilutive capital. XOMA has 14 programs in registrational studies and has completed nine acquisitions since 2024. Updated Mar 18, 2026